Catalog No.
DHE22002
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Alpha-synuclein, PARK1, Non-A4 component of amyloid precursor, NACP, Non-A beta component of AD amyloid, SNCA
Concentration
1.64mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P37840
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PRX002, RG-7935, CAS: 1960462-19-4
Clone ID
Prasinezumab
Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data., PMID:39971932
Prasinezumab: A Bayesian Perspective on Its Efficacy., PMID:39868860
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data., PMID:39798255
An update on immune-based alpha-synuclein trials in Parkinson's disease., PMID:39666171
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial., PMID:39379705
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders., PMID:39313800
Investigating the Mechanisms of Antibody Binding to Alpha-Synuclein for the Treatment of Parkinson's Disease., PMID:39251364
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease., PMID:38622249
The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease., PMID:38139032
Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches., PMID:37893474
Single-neuron neurodegeneration as a degenerative model for Parkinson's disease., PMID:37721280
Monoclonal Antibodies in Neurodegenerative Disease May Work, But They Don't Help: A Perspective from Physicians., PMID:36442210
Prasinezumab and Cinpanemab - The Perspective of a Person with Parkinson's., PMID:36373296
Trial of Prasinezumab in Early-Stage Parkinson's Disease., PMID:35921451
Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression., PMID:34966256
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data., PMID:34659081
Immunotherapies for Parkinson's Disease: Progression of Clinical Development., PMID:34042040
For research use only. Not for human or drug use.
